Inhibitex, Inc. (NASDAQ:INHX) today announced its financial results
for the second quarter ended June 30, 2008. �We are pleased and
encouraged by the measurable progress we have made in all three of
our core antiviral development programs during the first half of
2008, most notably the clinical advancement of our shingles
compound, FV-100,� said Russell H. Plumb, president and chief
executive officer of Inhibitex. �With FV-100 entering a multiple
ascending dose trial following encouraging safety and
pharmacokinetic data from a recently-completed single ascending
dose trial, we are progressing well toward our goal of advancing
the compound into a Phase II proof of concept trial around the end
of this year. Further, we continue to advance a number of compounds
from both our HCV nucleoside polymerase inhibitor and HIV integrase
inhibitor programs through lead optimization. Our HCV program
appears particularly promising at this juncture. Accordingly, in
the near-term we are assigning it a higher priority and have
re-aligned our internal resources in order to maximize the
potential of identifying a lead clinical candidate from the program
around the end of this year. As a result, we plan to complete the
lead optimization activities associated with our HIV program in the
first half of 2009.� Second Quarter 2008 Financial Results The
Company reported that it held $41.9 million in cash, cash
equivalents, short-term and long-term investments as of June 30,
2008, as compared to $50.3 million at December 31, 2007. The
Company reported a net loss for the second quarter of 2008 of $2.2
million, as compared to $2.3 million for the second quarter of last
year. Basic and diluted net loss per share was $0.05 for the second
quarter of 2008 as compared to $0.08 for the second quarter of
2007. The decrease in net loss in the second quarter of 2008 was
principally due to a $1.4 million reduction in research and
development expense associated with the settlement of prior
litigation related to a production and supply agreement, a decrease
in general and administrative expenses, and slightly higher
revenue, offset by an increase in research and development
expenditures associated with the clinical development of FV-100, as
well as the preclinical development of the Company�s HCV nucleoside
polymerase inhibitors and HIV integrase inhibitors and a decrease
in net interest income. Revenue for the second quarter of 2008 was
$0.8 million as compared to $0.7 million for the second quarter of
2007. The increase in revenue in 2008 was the result of higher
periodic research-associated support fees recognized by the Company
related to an existing license and development agreement. Research
and development expense for the second quarter of 2008 was $2.1
million, as compared to $1.7 million in the second quarter of 2007.
The $0.4 million increase in 2008 was the result of $0.7 million in
direct costs incurred in connection with the preclinical and
clinical development of FV-100, as well as increases of $0.4
million in sponsored research and preclinical expenses associated
with the Company�s HCV and HIV development programs, $0.3 million
in salaries, benefits and share-based compensation resulting from
an increase in personnel, and $0.4 million in various other
expenses, offset in part by a $1.4 million reduction in expense
associated with the settlement of prior litigation related to a
production and supply agreement. General and administrative expense
decreased to $1.2 million in the second quarter of 2008 from $2.0
million in the second quarter of 2007. The decrease of $0.8 million
was primarily the result of a decline of $0.6 million in salaries,
benefits and share-based compensation due to a non-recurring charge
for severance and termination benefits made in 2007 as well as a
reduction in personnel, a $0.1 million decrease in professional
fees, and a decrease in various other expenses of $0.1 million. The
Company recorded total share-based compensation expense of $0.4
million, or $0.01 per share, in the second quarter of 2008, of
which $0.2 million was recorded as research and development expense
and $0.2 million was recorded as general and administrative
expense. For the six months ended June 30, 2008, net loss was $5.7
million, as compared to $1.9 million for the same period in 2007.
Basic and diluted net loss per share was $0.13 in 2008 as compared
to $0.06 for the same period of 2007. The increase in net loss for
the six months ended June 30, 2008, was largely due to the same
factors as described above, as well as a significant decrease in
other income as a result of a $1.9 million gain recorded on the
sale of excess raw materials in 2007 that did not recur in 2008.
Recent Corporate Developments Phase I FV-100 Clinical Trial � On
August 5, 2008, the Company announced it had completed a Phase I
single ascending dose clinical trial of FV-100, its highly potent
and fast-acting orally available nucleoside analogue in development
for the treatment of shingles (herpes zoster). The Company reported
that there were no serious adverse events observed and that the
compound was generally well tolerated in the trial. In addition,
pharmacokinetic data demonstrated that all doses evaluated in the
trial maintained drug plasma levels of the active form of FV-100
that exceeded its EC50 for at least 24 hours. The Company also
reported that it had initiated enrollment in a multiple ascending
dose trial of FV-100 in healthy subjects, and anticipates
completing this trial in the fourth quarter of 2008. Settlement of
Litigation with Nabi Pharmaceuticals � On August 1, 2008, the
Company entered into a settlement agreement with Nabi
Pharmaceuticals (�Nabi�) in connection with an ongoing contractual
dispute between the two companies arising from the Company�s
termination of a production and supply agreement in 2006. The
Company agreed to pay Nabi $2.2 million to settle all remaining
claims. The Company had previously accrued a total of $3.6 million
in research and development expense associated with this dispute.
Accordingly, the Company recorded a $1.4 million reduction in
research and development expense with respect to this settlement in
the second quarter of 2008. NASDAQ Listing Transfer � On July 9,
2008, the Company announced that it had received approval from the
NASDAQ Listing Qualifications Staff to transfer its listing of
common stock from the NASDAQ Global Market to the NASDAQ Capital
Market. The listing transfer was in response to a letter the
Company received from NASDAQ in January 2008 regarding its
non-compliance with Marketplace Rule 4450(a)(5), which requires
companies to maintain a minimum bid price of $1.00 per share for
continued NASDAQ listing. The Company has an additional 180
calendar days from July 8, 2008, or until January 5, 2009, to
regain compliance with NASDAQ's minimum bid price requirement.
Financial Guidance The Company reported that the financial guidance
it previously provided for the year 2008 remains substantially
unchanged. Accordingly, the Company continues to anticipate that
its net cash burn for 2008, including the impact of the $2.2
million settlement with Nabi, will range from $17 to $19 million.
This financial guidance does not consider or reflect the financial
or operating impact of any additional collaborations, partnerships,
alliances, in-licensing, or other similar transactions that may
occur in the future. Financial guidance involves a high level of
uncertainty and is subject to numerous assumptions and factors.
With respect to the Company, these factors include, but are not
limited to: the funding requirements and time it may take to
conduct preclinical research, formulate and manufacture clinical
trial materials, and conduct clinical trials; the ability to enroll
subjects or patients in such trials and whether the results of
these clinical trials are favorable; receiving regulatory approvals
on a timely basis to proceed with the development of a drug
candidate; the cost of filing, prosecuting and enforcing patents or
other intellectual property rights; changes in the Company�s
strategy or development plans in the future; and the level of
general and administrative expenses needed to support the Company�s
business strategy and its publicly-traded status. Conference Call
and Webcast Information Russell H. Plumb, president and chief
executive officer of Inhibitex, and other members of management
will review the Company�s second quarter 2008 operating results and
financial position, as well as provide a general update on the
Company via webcast and conference call today at 8:30 a.m. EDT. To
access the conference call, please dial (888) 680-0878 (domestic)
or (617) 213-4855 (international) and reference the access code
29157221. A replay of the call will be available from 10:30 a.m.
EDT on August 12, until September 12, 2008, at midnight. To access
the replay, please dial (888) 286-8010 (domestic) or (617) 801-6888
(international) and reference the access code 72288440. A live
audio webcast of the call and the archived webcast will be
available in the News and Events section of the Inhibitex website
http://www.inhibitex.com under the News and Events category. About
Inhibitex Inhibitex, Inc., headquartered in Alpharetta, Georgia, is
a biopharmaceutical company focused on developing products to treat
and prevent serious infectious diseases. In addition to FV-100, the
Company�s development pipeline includes a series of HCV nucleoside
polymerase inhibitors and HIV integrase inhibitors. Inhibitex has
also licensed its proprietary MSCRAMM� protein technology to Wyeth
for the development of staphylococcal vaccines and to 3M for the
development of diagnostics. For additional information about the
Company, please visit www.inhibitex.com. Safe Harbor Statement This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve substantial risks and uncertainties. All statements,
other than statements of historical facts included in this press
release, including statements regarding the Company�s goal of
advancing FV-100 into a Phase II proof of concept trial; the
expected timing of completion of the Company�s ongoing multiple
ascending dose trial; the anticipated timing of completing lead
optimization activities and identifying clinical candidates for the
Company�s HCV and HIV programs; and financial guidance and the
anticipated net cash burn in 2008 are forward-looking statements.
These intentions, expectations, or potential may not be achieved in
the future and various important factors could cause actual results
or events to differ materially from the forward-looking statements
that the Company makes, including the risk that: the
pharmacokinetic or safety results of future preclinical and
clinical studies of FV-100 do not confirm prior findings or fail to
support its further development; the Company not being able to
enroll patients in its clinical trials in a timely manner; the
Company not obtaining regulatory approval to advance the
development of FV-100; either the Company, the U.S. Food and Drug
Administration (FDA) or an investigational review board (IRB)
suspending or terminating the clinical development of FV-100 for
safety or other reasons; the results of ongoing lead optimization
activities and future preclinical studies not supporting the
selection of a lead clinical candidate for the Company�s HIV and/or
HCV program in the anticipated time horizons, if at all; obtaining,
maintaining and protecting the intellectual property incorporated
into and supporting its product candidates; maintaining expenses,
revenues and other cash expenditures substantially in line with
planned or anticipated amounts; and other cautionary statements
contained elsewhere herein and in its Annual Report on Form 10-K
for the year ended December 31, 2007, as filed with the Securities
and Exchange Commission, or SEC, on March 14, 2008, and its
Quarterly Report on Form 10-Q for March 31, 2008, as filed with the
SEC on May 9, 2008. Given these uncertainties, you should not place
undue reliance on these forward-looking statements, which apply
only as of the date of this press release. There may be events in
the future that the Company is unable to predict accurately, or
over which it has no control. The Company's business, financial
condition, results of operations and prospects may change. The
Company may not update these forward-looking statements, even
though its situation may change in the future, unless it has
obligations under the Federal securities laws to update and
disclose material developments related to previously disclosed
information. The Company qualifies all of the information contained
in this press release, and particularly its forward-looking
statements, by these cautionary statements. Inhibitex� and MSCRAMM�
are registered trademarks of Inhibitex, Inc. � � INHIBITEX, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) � � June 30,
December 31, 2008 2007 ASSETS Current assets: Cash and cash
equivalents $ 13,532,642 $ 14,178,143 Short-term investments
27,965,920 36,088,309 Prepaid expenses and other current assets
840,071 1,058,426 Accounts receivable � 187,332 � � 44,988 � Total
current assets 42,525,965 51,369,866 Property and equipment, net.
2,523,618 2,564,345 Long-term investments � 400,480 � � � � Total
assets $ 45,450,063 � $ 53,934,211 � � � LIABILITIES AND
STOCKHOLDERS� EQUITY Current liabilities: Accounts payable $
1,005,956 $ 1,160,351 Accrued expenses 3,405,457 6,605,253 Current
portion of notes payable 312,500 312,500 Current portion of capital
lease obligations 388,112 698,151 Current portion of deferred
revenue 941,667 441,667 Other current liabilities � 154,824 � �
154,824 � Total current liabilities 6,208,516 9,372,746 Long-term
liabilities: Notes payable, net of current portion 546,875 703,125
Capital lease obligations, net of current portion � 68,710 Deferred
revenue, net of current portion 312,500 387,500 Other liabilities,
net of current portion � 1,149,944 � � 1,202,328 � Total long-term
liabilities � 2,009,319 � � 2,361,663 � Total liabilities 8,217,835
11,734,409 Stockholders' equity: Preferred stock, $.001 par value;
5,000,000 shares authorized at June 30, 2008 and December 31, 2007;
none issued and outstanding � � Common stock, $.001 par value;
75,000,000 shares authorized at June 30, 2008 and December 31,
2007; 43,048,212 and 42,785,318 shares issued and outstanding at
June 30, 2008 and December 31, 2007, respectively 43,048 42,785
Common stock warrants 15,551,492 15,551,492 Accumulated other
comprehensive income 6,352 106,480 Additional paid-in capital
241,422,983 240,634,018 Accumulated deficit � (219,791,647 ) �
(214,134,973 ) Total stockholders' equity � 37,232,228 � �
42,199,802 � Total liabilities and stockholders' equity $
45,450,063 � $ 53,934,211 � � � � � � INHIBITEX, INC. CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) � � Three Months
Ended Six Months Ended June 30, June 30, � 2008 � � 2007 � � 2008 �
� 2007 � Revenue: License fees and milestones $ 412,500 $ 412,500 $
825,000 $ 825,000 Collaborative research and development 375,000
250,000 750,000 500,000 Grants and other revenue � - � � 22,500 � �
- � � 28,500 � Total revenue 787,500 685,000 1,575,000 1,353,500
Operating expense: Research and development 2,108,102 1,678,463
5,514,149 3,245,037 General and administrative � 1,222,339 � �
1,961,906 � � 2,563,907 � � 3,268,064 � Total operating expense �
3,330,441 � � 3,640,369 � � 8,078,056 � � 6,513,101 � Loss from
operations (2,542,941 ) (2,955,369 ) (6,503,056 ) (5,159,601 )
Other (expense) income, net 3,054 (1,013 ) 14,480 1,944,579
Interest income, net � 331,012 � � 632,066 � � 831,902 � �
1,352,905 � Net loss $ (2,208,875 ) $ (2,324,316 ) $ (5,656,674 ) $
(1,862,117 ) � � Basic and diluted net loss per Share � $ (0.05 ) $
(0.08 ) $ (0.13 ) $ (0.06 ) � Weighted average shares used to
compute basic and diluted net loss per share � 42,909,471 � �
30,812,510 � � 42,850,270 � � 30,659,861 � �
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024